New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS ® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen. ROCKVILLE, ...

Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† ...

(Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop ...

Aurinia Pharmaceuticals Inc. had a solid Q3 and announced cost cuts, sparking rumors of potential acquisition and continued ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial ...

The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that a total of 33 studies, funded by the organization or supported by its clinical research ...

Several focus on Childhood-Onset Systemic Lupus ... Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial Abstract #0662: Deucravacitinib, a First-in ...

Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...

Jean-Philippe Parain on the BMW 5 Series LWB, reclining r ...

Having battled systemic lupus erythematosus for over 20 years and recently suffering from kidney failure, she filmed a final farewell to her father, reassuring him, “I will no longer trouble you.” ...